Gene Therapy Compositions for Treating Cardiovascular Diseases
A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart.
In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenges presented by failing hearts, chronic pressure overload, and cardiac energy metabolism. These conditions necessitate a solution that can enhance cardiac function, reduce hypertrophic markers, and optimize energy utilization with the heart muscle.
Researchers at The Ohio State University have developed a gene therapy solution that enables the precise modulation of CPT1a expression, influencing critical cardiac functions and survival mechanisms. CPT1a plays a pivotal role in determining the rate of long-chain fatty acid oxidation in the heart. The OSU researchers have shown that increasing CPT1a expression in the heart offers protection against functional decline during hypertrophic decompensation, leading to improved ejection fraction with chronic pressure overload.
Provisional patent application filed